INSTIL BIO INC (TIL) Stock Price & Overview
NASDAQ:TIL • US45783C2008
Current stock price
The current stock price of TIL is 8.03 USD. Today TIL is down by -2.55%. In the past month the price decreased by -8.33%. In the past year, price decreased by -45.04%.
TIL Key Statistics
- Market Cap
- 54.443M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.39
- Dividend Yield
- N/A
TIL Stock Performance
TIL Stock Chart
TIL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TIL. When comparing the yearly performance of all stocks, TIL is a bad performer in the overall market: 91.8% of all stocks are doing better.
TIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TIL. The financial health of TIL is average, but there are quite some concerns on its profitability.
TIL Earnings
TIL Forecast & Estimates
8 analysts have analysed TIL and the average price target is 54.06 USD. This implies a price increase of 573.23% is expected in the next year compared to the current price of 8.03.
TIL Groups
Sector & Classification
TIL Financial Highlights
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.39. The EPS increased by 1.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.45% | ||
| ROE | -62.34% | ||
| Debt/Equity | 0.7 |
TIL Ownership
TIL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.49 | 380.121B | ||
| AMGN | AMGEN INC | 15.48 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.06 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.43 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.31 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TIL
Company Profile
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Company Info
IPO: 2021-03-19
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 14
Phone: 13025310855
INSTIL BIO INC / TIL FAQ
What does TIL do?
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
What is the current price of TIL stock?
The current stock price of TIL is 8.03 USD. The price decreased by -2.55% in the last trading session.
Does TIL stock pay dividends?
TIL does not pay a dividend.
How is the ChartMill rating for INSTIL BIO INC?
TIL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of INSTIL BIO INC (TIL)?
INSTIL BIO INC (TIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.39).
Can you provide the ownership details for TIL stock?
You can find the ownership structure of INSTIL BIO INC (TIL) on the Ownership tab.